Safety, Tolerability, and PK of AH-008 Following Single Ascending Dose in Healthy Subjects

This is a Phase 1, first-in-human (FIH), randomized, double-blind, placebo-controlled, parallel-group, single ascending dose (SAD) study to evaluate the safety, tolerability, and pharmacokinetics of AH-008 administered as a single intravenous infusion in healthy adult subjects. Four sequential dose cohorts will be evaluated, each with sentinel dosing and SRC-reviewed dose escalation.

NCT Number	NCT07697560
Lead Sponsor	AnHorn Medicines Co. Ltd.
Conditions	Chemotherapy-induced Peripheral Neuropathy (CIPN)
Enrollment	32 participants
Start Date	2026-06-10
Primary Completion	2026-09 (estimated)
Study Completion	2026-09 (estimated)
Updated on ClinicalTrials.gov	2026-07-29